

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
2 December 2004 (02.12.2004)

PCT

(10) International Publication Number  
**WO 2004/104593 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/574**,  
33/536

Michael [DE/DE]; Hansastrasse 110, 81373 München  
(DE). **ZOLG, Werner** [DE/DE]; Sportplatzweg 4A,  
82362 Weilheim (DE).

(21) International Application Number:  
PCT/EP2004/005598

(74) Common Representative: **ROCHE DIAGNOSTICS  
GMBH**; c/o Dr. W. Naser, Patent Department (TR-E),  
Postfach 11 52, 82372 Penzberg (DE).

(22) International Filing Date: 25 May 2004 (25.05.2004)

(25) Filing Language: English

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(26) Publication Language: English

(30) Priority Data:  
03011158.7 26 May 2003 (26.05.2003) EP

(71) Applicant (*for DE only*): **ROCHE DIAGNOSTICS  
GMBH** [DE/DE]; Sandhofer Strasse 116, 68305  
Mannheim (DE).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except DE, US*): **F.  
HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacher-  
strasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BERNDT, Peter**  
[DE/CH]; Mittlere Strasse 138, CH-4056 Basel (CH).  
**HAGMANN, Marie-luise** [DE/DE]; Saalangerstrasse 42,  
82377 Penzberg (DE). **LANGEN, Hanno** [DE/DE]; Im  
Wolfischbuehl 27/4, 79585 Steinen (DE). **PALME, Stefan**  
[DE/DE]; Hochfeldstrasse 19, 82377 Penzberg (DE).  
**ROESSLER, Markus** [DE/DE]; Eichenstrasse 9a, 82110  
Germering (DE). **ROLLINGER, Wolfgang** [DE/DE];  
Kaiser-Heinrich-Strasse 10, 82398 Polling (DE). **TACKE,**

Published:  
— with international search report

*For two-letter codes and other abbreviations, refer to the "Guide-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF PROTEIN MASP AS A MARKER FOR COLORECTAL CANCER

(57) Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein MASP in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring MASP in said sample. Measurement of MASP can, e.g., be used in the early detection or diagnosis of colorectal cancer.

WO 2004/104593 A1

### Use of protein MASP as a marker for colorectal cancer

The present invention relates to the diagnosis of colorectal cancer. It discloses the use of MASP (maspin precursor) protein in the diagnosis of colorectal cancer. Furthermore, it especially relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring MASP in said sample. Measurement of MASP can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Cancer remains a major public health challenge despite progress in detection and therapy. Amongst the various types of cancer, colorectal cancer (=CRC) is one of the most frequent cancers in the Western world.

The earlier cancer can be detected/diagnosed, the better is the overall survival rate. This is especially true for CRC. The prognosis in advanced stages of tumor is poor. More than one third of the patients will die from progressive disease within five years after diagnosis, corresponding to a survival rate of about 40% for five years. Current treatment is only curing a fraction of the patients and clearly has the best effect on those patients diagnosed in an early stage of disease.

With regard to CRC as a public health problem, it is essential that more effective screening and preventative measures for colorectal cancer be developed.

The earliest detection procedures available at present for colorectal cancer involve using tests for fecal blood or endoscopic procedures. However, significant tumor size must typically exist before fecal blood is detected. The sensitivity of the guaiac-based fecal occult blood tests is ~26%, which means 74% of patients with malignant lesions will remain undetected (Ahlquist, D.A., *Gastroenterol. Clin. North Am.* 26 (1997) 41-55). The visualization of precancerous and cancerous lesions represents the best approach to early detection, but colonoscopy is invasive with significant costs, risks, and complications (Silvis, S.E., et al., *JAMA* 235 (1976) 928-930; Geenen, J.E., et al., *Am. J. Dig. Dis.* 20 (1975) 231-235; Anderson, W.F., et al., *J. Natl. Cancer Institute* 94 (2002) 1126-1133).

In the recent years a tremendous amount of so-called colon specific or even so-called colorectal cancer specific genes has been reported. The vast majority of the corresponding research papers or patent applications are based on data obtained by

analysis of RNA expression patterns in colon (cancer) tissue versus a different tissue or an adjacent normal tissue, respectively. Such approaches may be summarized as differential mRNA display techniques.

5 As an example for data available from mRNA-display techniques, WO 01/96390 shall be mentioned and discussed. This application describes and claims more than two hundred isolated polynucleotides and the corresponding polypeptides as such, as well as their use in the detection of CRC. However, it is general knowledge that differences on the level of mRNA are not mirrored by the level of the corresponding proteins. A protein encoded by a rare mRNA may be found in very high amounts and a protein encoded by an abundant mRNA may nonetheless be hard to detect and find at all. This lack of correlation between mRNA-level and protein level is due to reasons like mRNA stability, efficiency of translation, stability of the protein, etc.

15 There also are recent approaches investigating the differences in protein patterns between different tissues or between healthy and diseased tissue in order to identify candidate marker molecules which might be used in the diagnosis of CRC. Brünagel, G., et al., *Cancer Research* 62 (2002) 2437-2442 have identified seven nuclear matrix proteins which appear to be more abundant in CRC tissue as compared to adjacent normal tissue. No data from liquid samples obtained from an individual are reported.

20 WO 02/078636 reports about nine colorectal cancer-associated spots as found by surface-enhanced laser desorption and ionization (SELDI). These spots are seen more frequently in sera obtained from patients with CRC as compared to sera obtained from healthy controls. However, the identity of the molecule(s) comprised in such spot, e.g., its (their sequence), is not known.

30 Despite the large and ever growing list of candidate protein markers in the field of CRC, to date clinical/diagnostic utility of these molecules is not known. In order to be of clinical utility a new diagnostic marker as a single marker should be at least as good as the best single marker known in the art. Or, a new marker should lead to a progress in diagnostic sensitivity and/or specificity either if used alone or in combination with one or more other markers, respectively. The diagnostic

sensitivity and/or specificity of a test is best assessed by its receiver-operating characteristics, which will be described in detail below.

At present, only diagnostic blood tests based on the detection of carcinoembryonic antigen (CEA), a tumor-associated glycoprotein, are available to assist diagnosis in  
5 the field of CRC. CEA is increased in 95% of tissue samples obtained from patients with colorectal, gastric, and pancreatic cancers and in the majority of breast, lung, and head and neck carcinomas (Goldenberg, D.M., et al., J. Natl. Cancer Inst. (Bethesda) 57 (1976) 11-22). Elevated CEA levels have also been reported in  
10 patients with nonmalignant disease, and many patients with colorectal cancer have normal CEA levels in the serum, especially during the early stage of the disease (Carriquiry, L.A., and Pineyro, A., Dis. Colon Rectum 42 (1999) 921-929; Herrera, M.A., et al., Ann. Surg. 183 (1976) 5-9; Wanebo, H.J., et al., N. Engl. J. Med. 299 (1978) 448-451). The utility of CEA as measured from serum or plasma in detecting  
15 recurrences is reportedly controversial and has yet to be widely applied (Martell, R.E., et al., Int. J. Biol. Markers 13 (1998) 145-149; Moertel, C.G., et al., JAMA 270 (1993) 943-947).

In light of the available data, serum CEA determination possesses neither sensitivity nor the specificity to enable its use as a screening test for colorectal cancer in the  
20 asymptomatic population (Reynoso, G., et al., JAMA 220 (1972) 361-365; Sturgeon, C., Clinical Chemistry 48 (2002) 1151-1159).

Whole blood, serum or plasma are the most widely used sources of sample in clinical routine. The identification of an early CRC tumor marker that would allow  
25 reliable cancer detection or provide early prognostic information could lead to a diagnostic assay that would greatly aid in the diagnosis and in the management of this disease. Therefore, an urgent clinical need exists to improve the diagnosis of CRC from blood. It is especially important to improve the early diagnosis of CRC, since for patients diagnosed early on chances of survival are much higher as compared to those diagnosed at a progressed stage of disease.

It was the task of the present invention to investigate whether a new marker can be  
30 identified which may aid in CRC diagnosis.

Surprisingly, it has been found that use of protein MASP can at least partially overcome the problems known from the state of the art.

5 The present invention therefore relates to a method for the diagnosis of colorectal cancer comprising the steps of a) providing a liquid sample obtained from an individual, b) contacting said sample with a specific binding agent for MASP under conditions appropriate for formation of a complex between said binding agent and MASP, and c) correlating the amount of complex formed in (b) to the diagnosis of colorectal cancer. A preferred method uses a liquid sample obtained from an individual.

10 Another preferred embodiment of the invention is a method for the diagnosis of colorectal cancer comprising the steps of a) contacting a liquid sample obtained from an individual with a specific binding agent for MASP under conditions appropriate for formation of a complex between said binding agent and MASP, and  
15 b) correlating the amount of complex formed in (a) to the diagnosis of colorectal cancer.

As the skilled artisan will appreciate, any such diagnosis is made *in vitro*. The patient sample is discarded afterwards. The patient sample is solely used for the *in vitro* diagnostic method of the invention and the material of the patient sample is not transferred back into the patient's body. Typically, the sample is a liquid  
20 sample.

The protein MASP (maspin precursor; Swiss-PROT: P36952) is characterized by the sequence given in SEQ ID NO: 1. The cloned human maspin cDNA encodes a 42-kDa protein that shares homology with the serpin superfamily of protease inhibitors. Immunostaining studies demonstrate that maspin is found in the  
25 extracellular matrix and at the plasma membrane (Zou, Z., et al., *Science* 263 (1994) 526-529).

The human MASP gene (SERPINB5 of PI5) was originally isolated from normal mammary epithelium by subtractive hybridization on the basis of its expression at the mRNA level (Zou et al., *supra*). Maspin was expressed in normal mammary  
30 epithelial cells but not in most mammary carcinoma cell lines. Zou et al. (*supra*) showed that its expression reduces the ability of transformed cells to induce tumor

formation and metastasis, suggesting that the maspin gene encodes a tumor suppressor.

5 Bass, R., et al. (J. Biol. Chem. 277 (2002) 46845-46848) characterized eukaryotic maspin and found that it had no protease inhibitory effect against any of the proteolytic systems tested. It did, however, inhibit the migration of both tumor and vascular smooth muscle cells.

10 Song, S.Y., et al. (Digestive Diseases and Sciences 47 (2002) 1831-1835) studied the expression of maspin in colon cancers by immunohistochemical staining of tissue sections from adenomas, adenocarcinomas and metastatic adenocarcinomas. The immunoreactivity of maspin found by Song et al. (supra) was cytoplasmic, with some nuclear staining. More than 90% of adenoma, 75% of adenocarcinoma and 47% of metastatic carcinoma tissue sections stained positive for maspin. This study had the limitation that no quantitative assay system, such as western blot analysis, was used. The level of expression in comparison to the adjacent normal colon tissue  
15 was not assessed.

As obvious to the skilled artisan, the present invention shall not be construed to be limited to the full-length protein MASP of SEQ ID NO :1. Physiological or artificial fragments of MASP, secondary modifications of MASP, as well as allelic variants of MASP are also encompassed by the present invention. Artificial fragments  
20 preferably encompass a peptide produced synthetically or by recombinant techniques, which at least comprises one epitope of diagnostic interest consisting of at least 6 contiguous amino acids as derived from the sequence disclosed in SEQ ID NO:1. Such fragment may advantageously be used for generation of antibodies or as a standard in an immunoassay. More preferred the artificial fragment comprises  
25 at least two epitopes of interest appropriate for setting up a sandwich immunoassay.

In preferred embodiments, the novel marker MASP may be used for monitoring as well as for screening purposes.

When used in patient monitoring the diagnostic method according to the present invention may help to assess tumor load, efficacy of treatment and tumor  
30 recurrence in the follow-up of patients. Increased levels of MASP are directly correlated to tumor burden. After chemotherapy a short term (few hours to 14

days) increase in MASP may serve as an indicator of tumor cell death. In the follow-up of patients (from 3 months to 10 years) an increase of MASP can be used as an indicator for tumor recurrence.

5 In a preferred embodiment the diagnostic method according to the present invention is used for screening purposes. I.e., it is used to assess subjects without a prior diagnosis of CRC by measuring the level of MASP and correlating the level measured to the presence or absence of CRC.

10 Colorectal cancer most frequently progresses from adenomas (polyps) to malignant carcinomas. The different stages of CRC used to be classified according to Dukes' stages A to D.

The staging of cancer is the classification of the disease in terms of extent, progression, and severity. It groups cancer patients so that generalizations can be made about prognosis and the choice of therapy.

15 Today, the TNM system is the most widely used classification of the anatomical extent of cancer. It represents an internationally accepted, uniform staging system. There are three basic variables: T (the extent of the primary tumor), N (the status of regional lymph nodes) and M (the presence or absence of distant metastases). The TNM criteria are published by the UICC (International Union Against Cancer), Sobin, L.H., Wittekind, Ch. (eds): TNM Classification of Malignant Tumours, fifth  
20 edition, 1997).

25 What is especially important is, that early diagnosis of CRC translates to a much better prognosis. Malignant tumors of the colorectum arise from benign tumors, i.e. from adenoma. Therefore, best prognosis have those patients diagnosed at the adenoma stage. Patients diagnosed as early as in stage T<sub>is</sub>, N0, M0 or T1-3; N0; M0, if treated properly have a more than 90% chance of survival 5 years after diagnosis as compared to a 5-years survival rate of only 10% for patients diagnosed when distant metastases are already present.

In the sense of the present invention early diagnosis of CRC refers to a diagnosis at a pre-malignant state (adenoma) or at a tumor stage where no metastases at all

(neither proximal nor distal), i.e., adenoma, T<sub>is</sub>, N0, M0 or T1-4; N0; M0 are present. T<sub>is</sub> denotes carcinoma *in situ*.

In a preferred embodiment the detection of MASP is used to diagnose CRC as early as in the adenoma stage.

- 5 It is further preferred, that CRC is diagnosed when it has not yet fully grown through the bowel wall and thus neither the visceral peritoneum is perforated nor other organs or structures are invaded, i.e., that diagnosis is made at any stage from T<sub>is</sub>; N0; M0 to T3; N0; M0 (=T<sub>is</sub>-3; N0; M0).

10 The diagnostic method according to the present invention is based on a liquid sample which is derived from an individual. Unlike to methods known from the art MASP is specifically measured from this liquid sample by use of a specific binding agent.

15 A specific binding agent is, e.g., a receptor for MASP, a lectin binding to MASP or an antibody to MASP. A specific binding agent has at least an affinity of 10<sup>7</sup> l/mol for its corresponding target molecule. The specific binding agent preferably has an affinity of 10<sup>8</sup> l/mol or even more preferred of 10<sup>9</sup> l/mol for its target molecule. As the skilled artisan will appreciate the term specific is used to indicate that other biomolecules present in the sample do not significantly bind to with the binding agent specific for MASP. Preferably, the level of binding to a biomolecule other than the target molecule results in a binding affinity which is only 10%, more preferably only 5% of the affinity of the target molecule or less. A most preferred specific binding agent will fulfill both the above minimum criteria for affinity as well as for specificity.

25 A specific binding agent preferably is an antibody reactive with MASP. The term antibody refers to a polyclonal antibody, a monoclonal antibody, fragments of such antibodies, as well as to genetic constructs comprising the binding domain of an antibody.

30 The term antibody refers to a polyclonal antibody, a monoclonal antibody, fragments of such antibodies, as well as genetic constructs comprising the binding domain of an antibody. Any antibody fragment retaining the above criteria of a

specific binding agent can be used. Antibodies are generated by state of the art procedures, e.g., as described in Tijssen (Tijssen, P., Practice and theory of enzyme immunoassays 11 (1990) the whole book, especially pages 43-78; Elsevier, Amsterdam). In addition, the skilled artisan is well aware of methods based on immunosorbents that can be used for the specific isolation of antibodies. By these means the quality of polyclonal antibodies and hence their performance in immunoassays can be enhanced. (Tijssen, P., *supra*, pages 108-115).

For the achievements as disclosed in the present invention polyclonal antibodies raised in rabbits have been used. However, clearly also polyclonal antibodies from different species, e.g. rats or guinea pigs, as well as monoclonal antibodies can also be used. Since monoclonal antibodies can be produced in any amount required with constant properties, they represent ideal tools in development of an assay for clinical routine. The generation and use of monoclonal antibodies to MASP in a method according to the present invention is yet another preferred embodiment.

As the skilled artisan will appreciate now, that MASP has been identified as a marker which is useful in the diagnosis of CRC, alternative ways may be used to reach a result comparable to the achievements of the present invention. For example, alternative strategies to generate antibodies may be used. Such strategies comprise amongst others the use of synthetic peptides, representing an epitope of MASP for immunization. Alternatively, DNA Immunization also known as DNA vaccination may be used.

For measurement the liquid sample obtained from an individual is incubated with the specific binding agent for MASP under conditions appropriate for formation of a binding agent MASP-complex. Such conditions need not be specified, since the skilled artisan without any inventive effort can easily identify such appropriate incubation conditions.

As a final step according to the method disclosed in the present invention the amount of complex is measured and correlated to the diagnosis of CRC. As the skilled artisan will appreciate there are numerous methods to measure the amount of the specific binding agent MASP-complex all described in detail in relevant textbooks (cf., e.g., Tijssen P., *supra*, or Diamandis, et al., eds. (1996) Immunoassay, Academic Press, Boston).

Preferably MASP is detected in a sandwich type assay format. In such assay a first specific binding agent is used to capture MASP on the one side and a second specific binding agent, which is labeled to be directly or indirectly detectable is used on the other side.

- 5 As mentioned above, it has surprisingly been found that MASP can be measured from a liquid sample obtained from an individual sample. No tissue and no biopsy sample is required to apply the marker MASP in the diagnosis of CRC.

In a preferred embodiment the method according to the present invention is practiced with serum as liquid sample material.

- 10 In a further preferred embodiment the method according to the present invention is practiced with plasma as liquid sample material.

In a further preferred embodiment the method according to the present invention is practiced with whole blood as liquid sample material.

- 15 Furthermore stool can be prepared in various ways known to the skilled artisan to result in a liquid sample as well. Such sample liquid derived from stool also represents a preferred embodiment according to the present invention.

- 20 Whereas application of routine proteomics methods to tissue samples, leads to the identification of many potential marker candidates for the tissue selected, the inventors of the present invention have surprisingly been able to detect protein MASP in a bodily fluid sample. Even more surprising they have been able to demonstrate that the presence of MASP in such liquid sample obtained from an individual can be correlated to the diagnosis of colorectal cancer.

- 25 Antibodies to MASP with great advantage can be used in established procedures, e.g., to detect colorectal cancer cells in situ, in biopsies, or in immunohistological procedures.

Preferably, an antibody to MASP is used in a qualitative (MASP present or absent) or quantitative (MASP amount is determined) immunoassay.

Measuring the level of protein MASP has proven very advantageous in the field of CRC. Therefore, in a further preferred embodiment, the present invention relates to use of protein MASP as a marker molecule in the diagnosis of colorectal cancer from a liquid sample obtained from an individual.

- 5 The term marker molecule is used to indicate that an increased level of the analyte MASP as measured from a bodily fluid of an individual marks the presence of CRC.

It is especially preferred to use the novel marker MASP in the early diagnosis of colorectal cancer.

- 10 The use of protein MASP itself, represents a significant progress to the challenging field of CRC diagnosis. Combining measurements of MASP with other known markers, like CEA, or with other markers of CRC yet to be discovered, leads to further improvements. Therefore in a further preferred embodiment the present invention relates to the use of MASP as a marker molecule for colorectal cancer in combination with one or more marker molecules for colorectal cancer in the  
15 diagnosis of colorectal cancer from a liquid sample obtained from an individual. In this regard, the expression "one or more" denotes 1 to 10, preferably 1 to 5, more preferred 3. Preferred selected other CRC markers with which the measurement of MASP may be combined are CEA, CA 19-9, CA 72-4, and/or CA 242. Thus, a very much preferred embodiment of the present invention is the use of protein MASP as  
20 a marker molecule for colorectal cancer in combination with one or more marker molecules for colorectal cancer in the diagnosis of colorectal cancer from a liquid sample obtained from an individual, whereby the at least one other marker molecule is selected from the group consisting of CEA, CA 19-9, CA 72-4, and CA 242.

- 25 Diagnostic reagents in the field of specific binding assays, like immunoassays, usually are best provided in the form of a kit, which comprises the specific binding agent and the auxiliary reagents required to perform the assay. The present invention therefore also relates to an immunological kit comprising at least one specific binding agent for MASP and auxiliary reagents for measurement of MASP.

- 30 Accuracy of a test is best described by its receiver-operating characteristics (ROC) (see especially Zweig, M. H., and Campbell, G., Clin. Chem. 39 (1993) 561-577).

The ROC graph is a plot of all of the sensitivity/specificity pairs resulting from continuously varying the decision thresh-hold over the entire range of data observed.

5 The clinical performance of a laboratory test depends on its diagnostic accuracy, or the ability to correctly classify subjects into clinically relevant subgroups. Diagnostic accuracy measures the test's ability to correctly distinguish two different conditions of the subjects investigated. Such conditions are for example health and disease or benign versus malignant disease.

10 In each case, the ROC plot depicts the overlap between the two distributions by plotting the sensitivity versus 1 - specificity for the complete range of decision thresholds. On the y-axis is sensitivity, or the true-positive fraction [defined as (number of true-positive test results) / (number of true-positive + number of false-negative test results)]. This has also been referred to as positivity in the presence of a disease or condition. It is calculated solely from the affected subgroup. On the x-axis is the false-positive fraction, or 1 - specificity [defined as (number of false-positive results) / (number of true-negative + number of false-positive results)]. It is an index of specificity and is calculated entirely from the unaffected subgroup. Because the true- and false-positive fractions are calculated entirely separately, by using the test results from two different subgroups, the ROC plot is independent of the prevalence of disease in the sample. Each point on the ROC plot represents a sensitivity/-specificity pair corresponding to a particular decision threshold. A test with perfect discrimination (no overlap in the two distributions of results) has an ROC plot that passes through the upper left corner, where the true-positive fraction is 1.0, or 100% (perfect sensitivity), and the false-positive fraction is 0 (perfect specificity). The theoretical plot for a test with no discrimination (identical distributions of results for the two groups) is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall in between these two extremes. (If the ROC plot falls completely below the 45° diagonal, this is easily remedied by reversing the criterion for "positivity" from "greater than" to "less than" or vice versa.) Qualitatively, the closer the plot is to the upper left corner, the higher the overall accuracy of the test.

One convenient goal to quantify the diagnostic accuracy of a laboratory test is to express its performance by a single number. The most common global measure is

the area under the ROC plot. By convention, this area is always  $\geq 0.5$  (if it is not, one can reverse the decision rule to make it so). Values range between 1.0 (perfect separation of the test values of the two groups) and 0.5 (no apparent distributional difference between the two groups of test values). The area does not depend only on  
5 a particular portion of the plot such as the point closest to the diagonal or the sensitivity at 90% specificity, but on the entire plot. This is a quantitative, descriptive expression of how close the ROC plot is to the perfect one (area = 1.0).

Clinical utility of the novel marker MASP has been assessed in comparison to and in combination with the established marker CEA using a receiver operator curve  
10 analysis (ROC; Zweig, M. H., and Campbell, G., Clin. Chem. 39 (1993) 561-577). This analysis has been based on well-defined patient cohorts consisting of 50 samples each from patients in T1-3; N0; M0, more progressed tumor, i.e., T4 and/or various severity of metastasis (N+ and/or M+), and healthy controls, respectively.

15 The diagnostic method based on measurement of MASP alone in comparison to the established marker CEA alone has been found to have an at least as good a diagnostic accuracy (sensitivity/specificity profile) as demonstrated by the area under the curve.

20 The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

### Description of the Figures

25 **Figure 1** Figure 1 shows a typical example of a 2D-gel, loaded with a tumor sample (left side), and a gel, loaded with a matched control sample (right side) obtained from adjacent healthy mucosa. The apparent molecular weight and the isoelectric point of MASP correspond to the theoretical values of about 40 kDa and 5.98, respectively. The circle in the enlarged section of these gels  
30 indicates the position for the protein MASP. This protein was not detectable by the same method in healthy mucosa.

**Figure 2**

5 Figure 2 shows a typical example of a Western-Blot. The gel was loaded with tissue lysates from colorectal tumor tissue and adjacent healthy control tissue from 4 patients (subject 36: rectum ca (carcinoma), Dukes B; subject 37: rectum ca, Dukes A; subject 10 39: colon ca, Dukes A; and subject 40: colon ca, Dukes B). Presence of MASP in the samples was tested using a polyclonal rabbit anti-MASP serum. Lanes containing tumor lysates are indicated with "T", lanes containing normal control tissue with "N". The marker lane containing a molecular weight protein standard is indicated by "Ma". Lanes containing recombinant MASP at different concentrations are indicated by "300", "1000", and "3000". The arrow indicates the position in the gel of the MASP band. All tumor samples give a strong signal at the position of MASP, whereas only a weak signal can be detected in the lysates from adjacent normal control tissue. This strong overexpression of MASP in tumor tissue from colorectal cancer patients is found 15 in 13 out of 13 subjects tested.

**Abbreviations**

	ABTS	2,2'-Azino-di- [3-ethylbenzthiazoline sulfonate (6)] diammonium salt
5	BSA	bovine serum albumin
	cDNA	complementary DNA
	CHAPS	(3-[(3-Cholamidopropyl)-dimethylammonio]- 1-propane- sulfonate)
	DMSO	dimethyl sulfoxide
10	DTT	dithiothreitol
	EDTA	ethylene diamine tetraacetic acid
	ELISA	enzyme-linked immunosorbent assay
	HRP	horseradish peroxidase
	IAA	iodacetamid
15	IgG	immunoglobulin G
	IEF	isoelectric focussing
	IPG	immobilized pH gradient
	LDS	lithium dodecyl sulfate
	MALDI-TOF	matrix-assisted laser desorption/ionisation-time of flight
20		mass spectrometry
	MES	mesityl, 2,4,6-trimethylphenyl
	OD	optical density
	PAGE	polyacrylamide gel electrophoresis
	PBS	phosphate buffered saline
25	PI	isoelectric point
	RTS	rapid translation system
	SDS	sodium dodecyl sulfate

### Example 1

#### Identification of MASP as a potential colorectal cancer marker

##### Sources of tissue

5 In order to identify tumor-specific proteins as potential diagnostic markers for colorectal cancer, analysis of three different kinds of tissue using proteomics methods is performed.

10 In total, tissue specimen from 10 patients suffering from colorectal cancer are analyzed. From each patient three different tissue types are collected from therapeutic resections: tumor tissue (>80% tumor) (T), adjacent healthy tissue (N) and stripped mucosa from adjacent healthy mucosa (M). The latter two tissue types serves as matched healthy control samples. Tissues are immediately snap frozen after resection and stored at  $-80^{\circ}\text{C}$  before processing. Tumors are diagnosed by histopathological criteria.

##### Tissue preparation

15 0.8-1.2 g of frozen tissue are put into a mortar and completely frozen by liquid nitrogen. The tissue is pulverized in the mortar, dissolved in the 10-fold volume (w/v) of lysis buffer (40 mM Na-citrate, 5 mM  $\text{MgCl}_2$ , 1% Genapol X-080, 0.02% Na-azide, Complete<sup>®</sup> EDTA-free [Roche Diagnostics GmbH, Mannheim, Germany, Cat. No. 1 873 580]) and subsequently homogenized in a Wheaton<sup>®</sup> glass homogenizer (20 x loose fitting, 20 x tight fitting). 3 ml of the homogenate are  
20 subjected to a sucrose-density centrifugation (10-60% sucrose) for 1 h at 4,500 x g. After this centrifugation step three fractions are obtained. The fraction on top of the gradient contains the soluble proteins and is used for further analysis.

##### Isoelectric focussing (IEF) and SDS-PAGE

25 For IEF, 3 ml of the suspension are mixed with 12 ml sample buffer (7 M urea, 2 M thiourea, 2% CHAPS, 0.4% IPG buffer pH 4-7, 0.5% DTT) and incubated for 1 h. The samples are concentrated in an Amicon<sup>®</sup> Ultra-15 device (Millipore GmbH, Schwalbach, Germany) and the protein concentration is determined using the Bio-Rad<sup>®</sup> protein assay (Cat.No. 500-0006; Bio-Rad Laboratories GmbH, München,

Germany) following the instructions of the supplier's manual. To a volume corresponding to 1.5 mg of protein sample buffer is added to a final volume of 350  $\mu$ l. This solution is used to rehydrate IPG strips pH 4-7 (Amersham Biosciences, Freiburg, Germany) overnight. The IEF is performed using the following gradient protocol: 1.) 1 minute to 500 V; 2.) 2 h to 3,500 V; 3.) 22 h at constant 3,500 V giving rise to 82 kVh. After IEF, strips are stored at  $-80^{\circ}\text{C}$  or directly used for SDS-PAGE.

Prior to SDS-PAGE the strips are incubated in equilibration buffer (6 M urea, 50 mM Tris/HCl, pH 8.8, 30% glycerol, 2% SDS), for reduction DTT (15 min, + 50 mg DTT/10 ml), and for alkylation IAA (15 min, + 235 mg iodacetamide/10 ml) is added. The strips are put on 12.5% polyacrylamide gels and subjected to electrophoresis at 1 W/gel for 1 h and thereafter at 17 W/gel. Subsequently, the gels are fixed (50% methanol, 10% acetate) and stained overnight with Novex<sup>TM</sup> Colloidal Blue Staining Kit (Invitrogen, Karlsruhe, Germany, Cat No. LC6025, 45-7101)

#### Detection of MASP as a potential marker for colorectal cancer

Each patient is analyzed separately by image analysis with the ProteomeWeaver<sup>®</sup> software (Definiens AG, Germany, München). In addition, all spots of the gel are excised by a picking robot and the proteins present in the spots are identified by MALDI-TOF mass spectrometry (Ultraflex<sup>TM</sup> Tof/Tof, Bruker Daltonik GmbH, Bremen, Germany). For each patient, 4 gels from the tumor sample are compared with 4 gels each from adjacent normal and stripped mucosa tissue and analyzed for distinctive spots corresponding to differentially expressed proteins. By this means, protein MASP is found to be specifically expressed or strongly overexpressed in tumor tissue and not detectable or less strongly expressed in healthy control tissue. It therefore – amongst many other proteins - qualifies as a candidate marker for use in the diagnosis of colorectal cancer.

## Example 2

### **Generation of antibodies to the colorectal cancer marker protein MASP**

Polyclonal antibody to the colorectal cancer marker protein MASP is generated for further use of the antibody in the measurement of serum and plasma and blood  
5 levels of MASP by immunodetection assays, e.g. Western Blotting and ELISA.

### Recombinant protein expression in E. coli

In order to generate antibodies to MASP, recombinant expression of the protein is performed for obtaining immunogens. The expression is done applying a combination of the RTS 100 expression system and E.coli. In a first step, the DNA  
10 sequence is analyzed and recommendations for high yield cDNA silent mutational variants and respective PCR-primer sequences are obtained using the “ProteoExpert RTS E.coli HY” system. This is a commercial web based service (www.proteoexpert.com). Using the recommended primer pairs, the “RTS 100 E.  
coli Linear Template Generation Set, His-tag” (Roche Diagnostics GmbH, Mannheim, Germany, Cat.No. 3186237) system to generate linear PCR templates  
15 from the cDNA and for in vitro transcription and expression of the nucleotide sequence coding for the MASP protein is used. For Western-blot detection and later purification, the expressed protein contains a His-tag. The best expressing variant is identified. All steps from PCR to expression and detection are carried out according  
20 to the instructions of the manufacturer. The respective PCR product, containing all necessary T7 regulatory regions (promoter, ribosomal binding site and T7 terminator) is cloned into the pBAD TOPO<sup>®</sup> vector (Invitrogen, Karlsruhe, Germany, Cat. No. K 4300/01) following the manufacturer’s instructions. For expression using the T7 regulatory sequences, the construct is transformed into E.  
25 coli BL 21 (DE 3) (Studier, F.W., et al., Methods Enzymol. 185 (1990) 60-89) and the transformed bacteria are cultivated in a 1 l batch for protein expression.

Purification of His-MASP fusion protein is done following standard procedures on a Ni-chelate column. Briefly, 1 l of bacteria culture containing the expression vector for the His-MASP fusion protein is pelleted by centrifugation. The cell pellet is  
30 resuspended in lysis buffer, containing phosphate, pH 8.0, 7 M guanidium chloride, imidazole and thioglycerole, followed by homogenization using a Ultra-Turrax<sup>®</sup>. Insoluble material is pelleted by high speed centrifugation and the supernatant is

applied to a Ni-chelate chromatographic column. The column is washed with several bed volumes of lysis buffer followed by washes with buffer, containing phosphate, pH 8,0 and Urea. Finally, bound antigen is eluted using a phosphate buffer containing SDS under acid conditions.

## 5 Production of monoclonal antibodies against the MASP

### a) Immunization of mice

12 week old A/J mice are initially immunized intraperitoneally with 100 µg MASP.. This is followed after 6 weeks by two further intraperitoneal immunizations at monthly intervals. In this process each mouse is administered 100 µg MASP adsorbed to aluminum hydroxide and  $10^9$  germs of *Bordetella pertussis*.  
10 Subsequently the last two immunizations are carried out intravenously on the 3rd and 2nd day before fusion using 100 µg MASP in PBS buffer for each.

### b) Fusion and cloning

Spleen cells of the mice immunized according to a) are fused with myeloma cells according to Galfre, G., and Milstein, C., Methods in Enzymology 73 (1981) 3-46.  
15 In this process ca.  $1 \cdot 10^8$  spleen cells of the immunized mouse are mixed with  $2 \cdot 10^7$  myeloma cells (P3X63-Ag8-653, ATCC CRL1580) and centrifuged (10 min at 300 g and 4° C.). The cells are then washed once with RPMI 1640 medium without fetal calf serum (FCS) and centrifuged again at 400 g in a 50 ml conical tube. The  
20 supernatant is discarded, the cell sediment is gently loosened by tapping, 1 ml PEG (molecular weight 4000, Merck, Darmstadt) is added and mixed by pipetting. After 1 min in a water-bath at 37°C., 5 ml RPMI 1640 without FCS is added drop-wise at room temperature within a period of 4-5 min. Afterwards 5 ml RPMI 1640 containing 10% FCS is added drop-wise within ca. 1 min, mixed thoroughly, filled  
25 to 50 ml with medium (RPMI 1640+10% FCS) and subsequently centrifuged for 10 min at 400 x g and 4°C. The sedimented cells are taken up in RPMI 1640 medium containing 10% FCS and sown in hypoxanthine-azaserine selection medium (100 mmol/l hypoxanthine, 1 µg/ml azaserine in RPMI 1640+10% FCS). Interleukin 6 at 100 U/ml is added to the medium as a growth factor.

After ca. 10 days the primary cultures are tested for specific antibody. MASP-positive primary cultures are cloned in 96-well cell culture plates by means of a fluorescence activated cell sorter. In this process again interleukin 6 at 100 U/ml is added to the medium as a growth additive.

5 c) Immunoglobulin isolation from the cell culture supernatants

The hybridoma cells obtained are sown at a density of  $1 \times 10^5$  cells per ml in RPMI 1640 medium containing 10% FCS and proliferated for 7 days in a fermenter (Thermodux Co., Wertheim/Main, Model MCS-104XL, Order No. 144-050). On average concentrations of 100  $\mu$ g monoclonal antibody per ml are obtained in the culture supernatant. Purification of this antibody from the culture supernatant is carried out by conventional methods in protein chemistry (e.g. according to Bruck, C., et al., Methods in Enzymology 121 (1986) 587-695).

Generation of polyclonal antibodies

a) Immunization

15 For immunization, a fresh emulsion of the protein solution (100  $\mu$ g/ml protein MASP) and complete Freund's adjuvant at the ratio of 1:1 is prepared. Each rabbit is immunized with 1 ml of the emulsion at days 1, 7, 14 and 30, 60 and 90. Blood is drawn and resulting anti-MASP serum used for further experiments as described in examples 3 and 4.

20 b) Purification of IgG (immunoglobulin G) from rabbit serum by sequential precipitation with caprylic acid and ammonium sulfate

One volume of rabbit serum is diluted with 4 volumes of acetate buffer (60 mM, pH 4.0). The pH is adjusted to 4.5 with 2 M Tris-base. Caprylic acid (25  $\mu$ l/ml of diluted sample) is added drop-wise under vigorous stirring. After 30 min the sample is centrifuged (13,000 x g, 30 min, 4°C), the pellet discarded and the supernatant collected. The pH of the supernatant is adjusted to 7.5 by the addition of 2 M Tris-base and filtered (0.2  $\mu$ m).

The immunoglobulin in the supernatant is precipitated under vigorous stirring by the drop-wise addition of a 4 M ammonium sulfate solution to a final concentration of 2 M. The precipitated immunoglobulins are collected by centrifugation (8,000 x g, 15 min, 4°C).

- 5 The supernatant is discarded. The pellet is dissolved in 10 mM NaH<sub>2</sub>PO<sub>4</sub>/NaOH, pH 7.5, 30 mM NaCl and exhaustively dialyzed. The dialysate is centrifuged (13,000 x g, 15 min, 4°C) and filtered (0.2 µm).

#### Biotinylation of polyclonal rabbit IgG

- 10 Polyclonal rabbit IgG is brought to 10 mg/ml in 10 mM NaH<sub>2</sub>PO<sub>4</sub>/NaOH, pH 7.5, 30 mM NaCl. Per ml IgG solution 50 µl Biotin -N-hydroxysuccinimide (3.6 mg/ml in DMSO) are added. After 30 min at room temperature, the sample is chromatographed on Superdex 200 (10 mM NaH<sub>2</sub>PO<sub>4</sub>/NaOH, pH 7.5, 30 mM NaCl). The fraction containing biotinylated IgG are collected. Monoclonal antibodies are biotinylated according to the same procedure.

#### 15 Digoxigenylation of polyclonal rabbit IgG

- 20 Polyclonal rabbit IgG is brought to 10 mg/ml in 10 mM NaH<sub>2</sub>PO<sub>4</sub>/NaOH, 30 mM NaCl, pH 7.5. Per ml IgG solution 50 µl digoxigenin-3-O-methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester (Roche Diagnostics, Mannheim, Germany, Cat. No. 1 333 054) (3.8 mg/ml in DMSO) are added. After 30 min at room temperature, the sample is chromatographed on Superdex<sup>®</sup> 200 (10 mM NaH<sub>2</sub>PO<sub>4</sub>/NaOH, pH 7.5, 30 mM NaCl). The fractions containing digoxigenylated IgG are collected. Monoclonal antibodies are labeled with digoxigenin according to the same procedure.

#### Example 3

- 25 **Western Blotting for the detection of MASP in human colorectal cancer tissue using polyclonal antibody as generated in Example 2.**

Tissue lysates from tumor samples and healthy control samples are prepared as described in Example 1, "Tissue preparation".

SDS-PAGE and Western-Blotting are carried out using reagents and equipment of Invitrogen, Karlsruhe, Germany. For each tissue sample tested, 10 µg of tissue lysate are diluted in reducing NuPAGE® (Invitrogen) SDS sample buffer and heated for 10 min at 95°C. Samples are run on 4-12% NuPAGE® gels (Tris-Glycine) in the MES running buffer system. The gel-separated protein mixture is blotted onto nitrocellulose membranes using the Invitrogen XCell II™ Blot Module (Invitrogen) and the NuPAGE® transfer buffer system. The membranes are washed 3 times in PBS/0.05% Tween-20 and blocked with Roti®-Block blocking buffer (A151.1; Carl Roth GmbH, Karlsruhe, Germany) for 2 h. The primary antibody, polyclonal rabbit anti-MASP serum (generation described in Example 2), is diluted 1:10,000 in Roti®-Block blocking buffer and incubated with the membrane for 1 h. The membranes are washed 6 times in PBS/0.05% Tween-20. The specifically bound primary rabbit antibody is labeled with an POD-conjugated polyclonal sheep anti-rabbit IgG antibody, diluted to 10 mU/ml in 0.5 x Roti®-Block blocking buffer. After incubation for 1 h, the membranes are washed 6 times in PBS/0.05% Tween-20. For detection of the bound POD-conjugated anti-rabbit antibody, the membrane is incubated with the Lumi-Light<sup>PLUS</sup> Western Blotting Substrate (Order-No. 2015196, Roche Diagnostics GmbH, Mannheim, Germany) and exposed to an autoradiographic film.

#### 20 Example 4

**ELISA for the measurement of MASP in human serum and plasma samples.**

For detection of MASP in human serum or plasma, a sandwich ELISA is developed. For capture and detection of the antigen, aliquots of the anti-MASP polyclonal antibody (see Example 2) are conjugated with biotin and digoxigenin, respectively.

25 Streptavidin-coated 96-well microwell plates are incubated with 100 µl biotinylated anti-MASP polyclonal antibody for 60 min at 10 µg/ml in 10 mM phosphate, pH 7.4, 1% BSA, 0.9% NaCl and 0.1% Tween-20. After incubation, plates are washed three times with 0.9% NaCl, 0.1% Tween-20. Wells are then incubated for 2 h with either a serial dilution of the recombinant protein (see Example 2) as standard antigen or with diluted plasma samples from patients. After binding of MASP, plates are washed three times with 0.9% NaCl, 0.1% Tween-20. For specific detection of bound MASP, wells are incubated with 100 µl of digoxigenylated anti-

30

MASP polyclonal antibody for 60 min at 10 µg/ml in 10 mM phosphate, pH 7.4, 1% BSA, 0.9% NaCl and 0.1% Tween-20. Thereafter, plates are washed three times to remove unbound antibody. In a next step, wells are incubated with 20 mU/ml anti-digoxigenin-POD conjugates (Roche Diagnostics GmbH, Mannheim, Germany, Catalog No. 1633716) for 60 min in 10 mM phosphate, pH 7.4, 1% BSA, 0.9% NaCl and 0.1% Tween-20. Plates are subsequently washed three times with the same buffer. For detection of antigen-antibody complexes, wells are incubated with 100 µl ABTS solution (Roche Diagnostics GmbH, Mannheim, Germany, Catalog No. 11685767) and OD is measured after 30-60 min at 405 nm with an ELISA reader.

**Example 5:**

**ROC analysis to assess clinical utility in terms of diagnostic accuracy.**

Accuracy is assessed by analyzing individual liquid samples obtained from well-characterized patient cohorts, i.e., 50 patients having undergone colonoscopy and found to be free of adenoma or CRC, 50 patients diagnosed and staged as T<sub>is</sub>-3, N0, M0 of CRC, and 50 patients diagnosed with progressed CRC, having at least tumor infiltration in at least one proximal lymph node or more severe forms of metastasis, respectively. CEA as measured by a commercially available assay (Roche Diagnostics, CEA-assay (Cat. No. 1 173 1629 for Elecsys<sup>®</sup> Systems immunoassay analyzer) and MASP measured as described above are quantified in a serum obtained from each of these individuals. ROC-analysis is performed according to Zweig, M. H., and Campbell, *supra*. Discriminatory power for differentiating patients in the group T<sub>is</sub>-3, N0, M0 from healthy individuals as measured by the area under the curve is found to be at least as good for MASP as compared to the established marker CEA.

Preliminary data indicate that MASP may also be very helpful in the follow-up of patients after surgery.

List of References

- Ahlquist, D.A., *Gastroenterol. Clin. North Am.* 26 (1997) 41-55
- Anderson, W.F., et al., *J. Natl. Cancer Institute* 94 (2002) 1126-1133
- Bass, R., et al., *J. Biol. Chem.* 277 (2002) 46845-46848
- 5 Bruck, C., et al., *Methods Enzymol.* 121 (1986) 587-695
- Brünagel, G., et al., *Cancer Research* 62 (2002) 2437-2442
- Carriquiry, L.A., and Pineyro, A., *Dis. Colon Rectum* 42 (1999) 921-929
- Diamandis, et al., eds. (1996) *Immunoassay*, Academic Press, Boston.
- Galfre, G., and Milstein, C., *Methods Enzymol.* 73 (1981) 3-46
- 10 Geenen, J.E., et al., *Am. J. Dig. Dis.* 20 (1975) 231-235
- Goldenberg, D.M., et al., *J. Natl. Cancer Inst. (Bethesda)* 57 (1976) 11-22
- Herrera, M.A., et al., *Ann. Surg.* 183 (1976) 5-9
- Martell, R.E., et al., *Int. J. Biol. Markers* 13 (1998) 145-149
- Moertel, C.G., et al., *JAMA* 270 (1993) 943-947
- 15 Reynoso, G., et al., *JAMA* 220 (1972) 361-365
- Silvis, S.E., et al., *JAMA* 235 (1976) 928-930
- Sobin, L.H., Wittekind, Ch. (eds), *TNM Classification of Malignant Tumours*, fifth edition, 1997
- Song, S.Y., et al., *Digestive Diseases and Sciences* 47 (2002) 1831-1835
- 20 Studier, F.W., et al., *Methods Enzymol.* 185 (1990) 60-89
- Sturgeon, C., *Clinical Chemistry* 48 (2002) 1151-1159
- Tijssen, P., *Practice and theory of enzyme immunoassays* 11 (1990) the whole book, especially pages 43-78; Elsevier, Amsterdam
- UICC (International Union Against Cancer), Sobin, L.H., Wittekind, Ch. (eds),
- 25 *TNM Classification of Malignant Tumours*, fifth edition, 1997
- Wanebo, H.J., et al., *N. Engl. J. Med.* 299 (1978) 448-451
- WO 01/96390
- WO 02/078636
- Zou, Z., et al., *Science* 263 (1994) 526-529
- 30 Zweig, M. H., and Campbell, G., *Clin. Chem.* 39 (1993) 561-577

## Patent Claims

1. A method for the diagnosis of colorectal cancer comprising the steps of
  - a) providing a liquid sample obtained from an individual,
  - b) contacting said sample with a specific binding agent for maspin precursor (MASP) under conditions appropriate for formation of a  
5 complex between said binding agent and MASP, and
  - c) correlating the amount of complex formed in (b) to the diagnosis of colorectal cancer.
  
- 10 2. The method according to claim 1, further characterized in that said sample is serum.
  
3. The method according to claim 1, further characterized in that said sample is plasma.
  
4. The method according to claim 1, further characterized in that said sample is whole blood.
  
- 15 5. Use of protein MASP as a marker molecule in the diagnosis of colorectal cancer from a liquid sample obtained from an individual.
  
6. Use of protein MASP as a marker molecule in the early diagnosis of colorectal cancer from a liquid sample obtained from an individual.
  
- 20 7. Use according to claim 6, wherein the early diagnosis is made with sample derived from CRC patients in the adenoma stage.
  
8. Use according to claim 6, wherein the early diagnosis is made with sample derived from CRC patients in stage T<sub>is</sub> -3; N0; M0.
  
- 25 9. Use of protein MASP as a marker molecule for colorectal cancer in combination with another marker molecule for colorectal cancer in the diagnosis of colorectal cancer from a liquid sample obtained from an individual.

10. An immunological kit comprising at least one specific binding agent for MASP and auxiliary reagents for measurement of MASP.

Figure 1:





Figure 2:





Ala Lys Glu Leu Glu Thr Val Asp Phe Lys Asp Lys Leu Glu Glu Thr  
 115 120 125

Lys Gly Gln Ile Asn Asn Ser Ile Lys Asp Leu Thr Asp Gly His Phe  
 130 135 140

Glu Asn Ile Leu Ala Asp Asn Ser Val Asn Asp Gln Thr Lys Ile Leu  
 145 150 155 160

Val Val Asn Ala Ala Tyr Phe Val Gly Lys Trp Met Lys Lys Phe Pro  
 165 170 175

Glu Ser Glu Thr Lys Glu Cys Pro Phe Arg Leu Asn Lys Thr Asp Thr  
 180 185 190

Lys Pro Val Gln Met Met Asn Met Glu Ala Thr Phe Cys Met Gly Asn  
 195 200 205

Ile Asp Ser Ile Asn Cys Lys Ile Ile Glu Leu Pro Phe Gln Asn Lys  
 210 215 220

His Leu Ser Met Phe Ile Leu Leu Pro Lys Asp Val Glu Asp Glu Ser  
 225 230 235 240

Thr Gly Leu Glu Lys Ile Glu Lys Gln Leu Asn Ser Glu Ser Leu Ser  
 245 250 255

Gln Trp Thr Asn Pro Ser Thr Met Ala Asn Ala Lys Val Lys Leu Ser  
 260 265 270

Ile Pro Lys Phe Lys Val Glu Lys Met Ile Asp Pro Lys Ala Cys Leu  
 275 280 285

Glu Asn Leu Gly Leu Lys His Ile Phe Ser Glu Asp Thr Ser Asp Phe  
 290 295 300

Ser Gly Met Ser Glu Thr Lys Gly Val Ala Leu Ser Asn Val Ile His  
 305 310 315 320

Lys Val Cys Leu Glu Ile Thr Glu Asp Gly Gly Asp Ser Ile Glu Val  
 325 330 335

Pro Gly Ala Arg Ile Leu Gln His Lys Asp Glu Leu Asn Ala Asp His  
340 345 350

Pro Phe Ile Tyr Ile Ile Arg His Asn Lys Thr Arg Asn Ile Ile Phe  
355 360 365

Phe Gly Lys Phe Cys Ser Pro  
370 375

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/005598A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 G01N33/574 G01N33/536

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, WPI Data, CHEM ABS Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SONG SANG YONG ET AL: "Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density." DIGESTIVE DISEASES AND SCIENCES. UNITED STATES AUG 2002, vol. 47, no. 8, August 2002 (2002-08), pages 1831-1835, XP009019409 ISSN: 0163-2116 the whole document	1-10

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

6 August 2004

Date of mailing of the international search report

15/09/2004

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

G. Willière

专利名称(译)	使用蛋白质MASP作为结直肠癌的标志物		
公开(公告)号	<a href="#">EP1631826A1</a>	公开(公告)日	2006-03-08
申请号	EP2004734663	申请日	2004-05-25
[标]申请(专利权)人(译)	罗氏诊断公司		
申请(专利权)人(译)	罗氏诊断有限公司 F.霍夫曼罗氏公司		
当前申请(专利权)人(译)	F.霍夫曼罗氏公司 罗氏诊断有限公司		
[标]发明人	BERNDT PETER HAGMANN MARIE LUISE LANGEN HANNO PALME STEFAN ROESSLER MARKUS ROLLINGER WOLFGANG TACKE MICHAEL ZOLG WERNER KARL JOHANN		
发明人	BERNDT, PETER HAGMANN, MARIE-LUISE LANGEN, HANNO PALME, STEFAN ROESSLER, MARKUS ROLLINGER, WOLFGANG TACKE, MICHAEL ZOLG, WERNER KARL, JOHANN		
IPC分类号	G01N33/574 G01N33/536		
CPC分类号	G01N33/57419 G01N2333/8107 G01N2800/52		
优先权	2003011158 2003-05-26 EP		
其他公开文献	EP1631826B1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本发明涉及结肠直肠癌的诊断。它公开了蛋白质MASP在结肠直肠癌诊断中的用途。本发明涉及一种通过测量所述样品中的MASP从个体衍生的液体样品诊断结肠直肠癌的方法。MASP的测量可以例如用于结肠直肠癌的早期检测或诊断。

